Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update
- PMID: 26620458
- PMCID: PMC5000795
- DOI: 10.4103/1008-682X.167721
Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update
Abstract
Phosphodiesterase isoenzymes 5 inhibitors (PDE5-Is) are the first-line therapy for erectile dysfunction (ED). The constant discoveries of nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) cell-signaling pathway for smooth muscle (SM) control in other urogenital tracts (UGTs) make PDE5-Is promising pharmacologic agents against other benign urological diseases. This article reviews the literature and contains some previously unpublished data about characterizations and activities of PDE5 and its inhibitors in treating urological disorders. Scientific discoveries have improved our understanding of cell-signaling pathway in NO/cGMP-mediated SM relaxation in UGTs. Moreover, the clinical applications of PDE5-Is have been widely recognized. On-demand PDE5-Is are efficacious for most cases of ED, while daily-dosing and combination with testosterone are recommended for refractory cases. Soluble guanylate cyclase (sGC) stimulators also have promising role in the management of severe ED conditions. PDE5-Is are also the first rehabilitation strategy for postoperation or postradiotherapy ED for prostate cancer patients. PDE5-Is, especially combined with α-adrenoceptor antagonists, are very effective for benign prostatic hyperplasia (BPH) except on maximum urinary flow rate (Q max ) with tadalafil recently proved for BPH with/without ED. Furthermore, PDE5-Is are currently under various phases of clinical or preclinical researches with promising potential for other urinary and genital illnesses, such as priapism, premature ejaculation, urinary tract calculi, overactive bladder, Peyronie's disease, and female sexual dysfunction. Inhibition of PDE5 is expected to be an effective strategy in treating benign urological diseases. However, further clinical studies and basic researches investigating mechanisms of PDE5-Is in disorders of UGTs are required.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5000795/bin/AJA-18-723-g002.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5000795/bin/AJA-18-723-g003.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5000795/bin/AJA-18-723-g004.gif)
Similar articles
-
Tadalafil for the treatment of benign prostatic hyperplasia.Expert Opin Pharmacother. 2019 Jun;20(8):929-937. doi: 10.1080/14656566.2019.1589452. Epub 2019 Mar 22. Expert Opin Pharmacother. 2019. PMID: 30901259 Review.
-
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.Eur Urol. 2011 Oct;60(4):809-25. doi: 10.1016/j.eururo.2011.06.037. Epub 2011 Jun 29. Eur Urol. 2011. PMID: 21726934 Review.
-
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.Eur Urol. 2016 Jul;70(1):124-133. doi: 10.1016/j.eururo.2015.12.048. Epub 2016 Jan 22. Eur Urol. 2016. PMID: 26806655 Review.
-
The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.Eur Urol. 2013 Mar;63(3):506-16. doi: 10.1016/j.eururo.2012.09.006. Epub 2012 Sep 11. Eur Urol. 2013. PMID: 23018163 Review.
-
The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.J Sex Med. 2014 Jun;11(6):1539-45. doi: 10.1111/jsm.12499. Epub 2014 Mar 13. J Sex Med. 2014. PMID: 24621088 Review.
Cited by
-
[First data from a digital health app for erectile dysfunction].Urologie. 2022 Sep;61(9):971-981. doi: 10.1007/s00120-022-01872-x. Epub 2022 Jun 20. Urologie. 2022. PMID: 35925101 Free PMC article. German.
-
On the Viability of Tadalafil-Based 18F-Radiotracers for In Vivo Phosphodiesterase 5 (PDE5) PET Imaging.ACS Omega. 2021 Aug 12;6(33):21741-21754. doi: 10.1021/acsomega.1c03315. eCollection 2021 Aug 24. ACS Omega. 2021. PMID: 34471776 Free PMC article.
-
Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review.J Clin Med. 2020 Apr 29;9(5):1284. doi: 10.3390/jcm9051284. J Clin Med. 2020. PMID: 32365529 Free PMC article. Review.
-
Obesity and Erectile Dysfunction: From Bench to Clinical Implication.World J Mens Health. 2019 May;37(2):138-147. doi: 10.5534/wjmh.180026. Epub 2018 Jul 25. World J Mens Health. 2019. PMID: 30079640 Free PMC article. Review.
References
-
- Conti M, Jin SL. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol. 1999;63:1–38. - PubMed
-
- Mayer B. Nitric oxide/cyclic GMP-mediated signal transduction. Ann N Y Acad Sci. 1994;733:357–64. - PubMed
-
- Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med. 1998;338:1397–404. - PubMed
-
- Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013;14:1333–44. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical